SNDX Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

64.08M

+734.42%

-0.583

-46.97%

70.79M

+253.22%

-0.542

-44.69%

85.54M

+125.36%

-0.432

-47.95%

Estimates Revision

The market is revising Upward the revenue expectations for Syndax Pharmaceuticals, Inc. (SNDX) for FY2025, with the revenue forecasts being adjusted by 0.16% over the past three months. During the same period, the stock price has changed by 32.04%.

Revenue Estimates for FY2025

Revise Upward

+0.16%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-2.52%

In Past 3 Month

Stock Price

Go Up

+32.04%

In Past 3 Month

12 Analyst Rating

Wall Street analysts forecast SNDX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SNDX is 36.00 USD with a low forecast of 22.00 USD and a high forecast of 56.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

12 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

22.00

Averages

36.00

High

56.00

Current: 0.000

Low

22.00

Averages

36.00

High

56.00

Barclays

NULL

Overweight

upgrade

$22 -> $35

2025-11-24

Reason

Barclays

Price Target

$22 -> $35

2025-11-24

upgrade

NULL

Overweight

Reason

Barclays raised the firm's price target on Syndax to $35 from $22 and keeps an Overweight rating on the shares. The firm updated the company's model after speaking with management.

JPMorgan

Anupam Rama

Overweight

downgrade

$40 -> $33

2025-11-12

Reason

JPMorgan

Anupam Rama

Price Target

$40 -> $33

2025-11-12

downgrade

Overweight

Reason

JPMorgan analyst Anupam Rama lowered the firm's price target on Syndax to $33 from $40 and keeps an Overweight rating on the shares. The firm updated models in the smid-cap biotechnology group.

UBS

Buy

maintain

$35 -> $38

2025-11-04

Reason

UBS

Price Target

$35 -> $38

2025-11-04

maintain

Buy

Reason

UBS raised the firm's price target on Syndax to $38 from $35 and keeps a Buy rating on the shares.

Barclays

Peter Lawson

Overweight

maintain

$19 -> $22

2025-11-04

Reason

Barclays

Peter Lawson

Price Target

$19 -> $22

2025-11-04

maintain

Overweight

Reason

Barclays analyst Peter Lawson raised the firm's price target on Syndax to $22 from $19 and keeps an Overweight rating on the shares. The company's "softer" Q3 was well telegraphed by management, and the focus can now turn to Q4 and Q1, with expectations for stronger growth, the analyst tells investors in a research note. The firm cites approval in NPM1 and better traction of Niktimvo for the target bump.

H.C. Wainwright

NULL -> Buy

initiated

$40

2025-10-16

Reason

H.C. Wainwright

Price Target

$40

2025-10-16

initiated

NULL -> Buy

Reason

H.C. Wainwright assumed coverage of Syndax with a Buy rating and $40 price target. The firm has conviction that Revuforj will expand its footprint across the relapsed/refractory setting. Revuforj is emerging as the foundational menin inhibitor in acute myeloid leukemia, the analyst tells investors in a research note.

Stifel

NULL

Buy

initiated

$44

2025-09-10

Reason

Stifel

Price Target

$44

2025-09-10

initiated

NULL

Buy

Reason

Stifel resumed coverage of Syndax with a Buy rating and $44 price target. The firm believes the commercial launches of two of the company's assets create a path to non-GAAP profitability in the second half of fiscal 2026. Each asset has $1B-plus in peak sales potential and are still in the very early stages of growth, the analyst tells investors in a research note. Stifel views Syndax's valuation as compelling at current levels.

Valuation Metrics

The current forward P/E ratio for Syndax Pharmaceuticals Inc (SNDX.O) is -11.30, compared to its 5-year average forward P/E of -7.65. For a more detailed relative valuation and DCF analysis to assess Syndax Pharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-7.65

Current PE

-11.30

Overvalued PE

-2.51

Undervalued PE

-12.79

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-3.25

Current EV/EBITDA

-9.32

Overvalued EV/EBITDA

3.24

Undervalued EV/EBITDA

-9.75

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

324.50

Current PS

5.81

Overvalued PS

1039.28

Undervalued PS

-390.28

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 195.05% over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders areSelling! The selling amount has increased 195.05% over the last month.

Sold

Bought

SNDX News & Events

Events Timeline

No data

News

7.5

01-07Globenewswire

Syndax Partners with WODA to Expand Access to Revuforj in Multiple Regions

8.0

2025-12-29NASDAQ.COM

Syndax Pharmaceuticals Inc. Offers 10.4% Annualized Return on $13 Put Options

5.0

2025-12-12Globenewswire

Syndax's Revuforj® Wins Best New Drug at 2025 Scrip Awards

People Also Watch

Frequently Asked Questions

What is Syndax Pharmaceuticals Inc (SNDX) stock price today?

The current price of SNDX is 21.39 USD — it has decreased -3.26 % in the last trading day.

What is Syndax Pharmaceuticals Inc (SNDX)'s business?

Syndax Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. It is focused on developing a pipeline of cancer therapies. Its product candidates include Revuforj and Niktimvo. It is developing Revuforj, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged also known as mixed lineage leukemia rearranged, acute leukemias including acute lymphoblastic leukemia and acute myeloid leukemia (AML), and necleophosmin 1, also known as NPM1, mutant AML. It is also exploring the use of Revuforj as a treatment in solid tumors, specifically its activity in metastatic colorectal cancer. It is also developing Niktimvo, a monoclonal antibody that blocks the colony stimulating factor 1 receptor (CSF-1R) in chronic graft-versus-host disease (cGVHD), as well as idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells.

What is the price predicton of SNDX Stock?

What is Syndax Pharmaceuticals Inc (SNDX)'s revenue for the last quarter?

Syndax Pharmaceuticals Inc revenue for the last quarter amounts to 45.87M USD, increased 266.97 % YoY.

What is Syndax Pharmaceuticals Inc (SNDX)'s earnings per share (EPS) for the last quarter?

Syndax Pharmaceuticals Inc. EPS for the last quarter amounts to -0.70 USD, decreased -28.57 % YoY.

What changes have occurred in the market's expectations for Syndax Pharmaceuticals Inc (SNDX)'s fundamentals?

How many employees does Syndax Pharmaceuticals Inc (SNDX). have?

Syndax Pharmaceuticals Inc (SNDX) has 270 emplpoyees as of January 09 2026.

What is Syndax Pharmaceuticals Inc (SNDX) market cap?

Today SNDX has the market capitalization of 1.86B USD.